50 mg Ketamine Autoinjector

The Defense Health Agency, specifically the Program Executive Office Operational Medical Systems (PEO OPMED) Warfighter Protection and Acute Care Project Management Office (WPAC PMO), is conducting a Request for Information (RFI) to develop a 50 mg ketamine autoinjector for battlefield analgesia. The agency is seeking industry partners with existing FDA-approved autoinjector platforms, FDA-inspected ketamine manufacturing capabilities, or active development of a 50 mg ketamine autoinjector. Interested manufacturers must submit a comprehensive capabilities statement by June 13, 2025, to Peter Mitchell via email. The RFI requires detailed information including intellectual property status, manufacturing capabilities, FDA approval history, experience with controlled substances, and estimated production capacity. Evaluation criteria will focus on companies' ability to meet technical specifications, manufacturing readiness, and potential for rapid deployment of the medical device.

This pre-solicitation notice is not set aside for any specific business category and is open to all qualified pharmaceutical manufacturers in the NAICS 325412 category. While no specific incumbent contractors are mentioned, the RFI indicates a desire to identify potential partners for developing a specialized medical device for military use. Respondents are limited to a 30-page submission and must provide per-unit cost information and monthly manufacturing potential. The document emphasizes that this is a market research effort and does not constitute a formal solicitation, with all submitted responses becoming government property. The RFI represents an initial step in potentially procuring a critical medical technology for battlefield medical treatment, focusing on developing an advanced ketamine autoinjector to support military medical care.